Gene

Compatibility (geochemistry)

Biology

Messenger RNA

Refractory (planetary science)

Materials science

Biochemistry

Anemia

Leukemia

Immunology

Myeloid leukemia

Acute leukemia

Monoclonal antibody

ABO blood group system

Reticulocyte

Internal medicine

Hemolysis

Blood transfusion

Composite material

Astrobiology

Monoclonal

Medicine

Gastroenterology

Rituximab

Antibody

Transfusion

BACKGROUND CD47 is a novel therapeutic target in the treatment of solid‐organ and hematologic malignancies. CD47 is also expressed on RBCs. Here, we report our experience of the RBC effects and the impact on blood bank testing and transfusion management in a Phase 1 trial of the humanized anti‐CD47 monoclonal antibody Hu5F9‐G4 in relapsed or primary refractory acute myeloid leukemia (AML) (NCT02678338). STUDY DESIGN AND METHODS Nineteen patients with relapsed or primary refractory AML treated across five UK centers were included for analysis. Patients received escalating doses of Hu5F9‐G4. Serial laboratory data were collected to evaluate impact on hemoglobin (Hb), markers of hemolysis (bilirubin, lactate dehydrogenase, reticulocyte count), transfusion requirements, and blood compatibility testing. RESULTS A decline in Hb was observed with drug administration (median Hb change, −1.0 g/dL; range, 0.4–1.6) with associated increase in transfusion requirements. Patients responded to transfusion with a median Hb increment per unit of 1.0 g/dL. RBC agglutination was seen in all cases without associated change in Hb, lactate dehydrogenase, bilirubin, or reticulocyte count. Nine of 19 (47%) patients developed a newly positive antibody screen with a pan‐agglutinin identified in plasma. Invalid ABO blood grouping occurred in 4 of 12 (33%) non–group O patients due to anomalous reactivity in the reverse ABO‐type results. CONCLUSIONS Treatment with Hu5F9‐G4 in patients with AML resulted in an Hb decline and increased transfusion requirements. Problems with ABO blood typing and compatibility testing were widely observed and should be expected by centers treating recipients of Hu5F9‐G4.

The effects of monoclonal anti‐CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia